Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S. Grover, Renu Balyan, Cliff Ding, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 7496–7497.

https://doi.org/10.1182/blood-2022-158869

Published: 2022

Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak

Blood (2022) 140 (Supplement 1): 2378–2380.

https://doi.org/10.1182/blood-2022-162150

Published: 2022

Journal Articles

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Matthew Mei, Sairah Ahmed, Amer Beitinjaneh, Natalie S. Grover, Carlos A. Ramos, Khong Bee Kang, Paul I. Nadler, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 12728–12730.

https://doi.org/10.1182/blood-2022-157131

Published: 2022

Journal Articles

Marked Therapeutic Efficacy of a Novel Polyethyleneglycol-SN38 Conjugate, EZN-2208, in Xenograft Models of Non-Hodgkin’s Lymphoma.

Puja Sapra, PhD, Mary Mehlig, BS, Jennifer Malaby, BS, Patricia Kraft, MS, Clifford Longley, MS, Hong Zhao, PhD, Lee M. Greenberger, PhD, Ivan D. Horak, MD

Blood (2007) 110 (11): 1397.

https://doi.org/10.1182/blood.V110.11.1397.1397

Published: 2007

Journal Articles

Recombinant Human Mannose-Binding Lectin (rhMBL) Binds to Human and Mouse Cancer Cells and Elicits Antitumor Activity in a MBL Knockout Mouse Model of Murine Cancer.

Puja Sapra, PhD, Patricia Kraft, MS, Mary Mehlig, BS, Zhihua Zhang, MD,PhD, Lee M. Greenberger, PhD, Ivan D. Horak, MD

Blood (2006) 108 (11): 1259.

https://doi.org/10.1182/blood.V108.11.1259.1259

Published: 2006

Journal Articles

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG 4 antibody immunotoxin

Chien-Hsing Chang, Puja Sapra, Sailaja S. Vanama, Hans J. Hansen, Ivan D. Horak, David M. Goldenberg

Blood (2005) 106 (13): 4308–4314.

https://doi.org/10.1182/blood-2005-03-1033

Published: 2005

Journal Articles

Preclinical Safety and Efficacy of Two Novel Immunotoxins Consisting of Ranpirnase (Rap) Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody in Human Non-Hodgkin’s Lymphoma Xenografts.

Puja Sapra, PhD, Chien-Hsing Chang, Ph.D, Sailaja Vanama, Ph.D, Sharon Singh, BA, Hans J. Hansen, Ph.D, Ivan D. Horak, M.D, David M. Goldenberg, M.D

Blood (2005) 106 (11): 346.

https://doi.org/10.1182/blood.V106.11.346.346

Published: 2005

Journal Articles

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

Sandra J. Strauss, MD, Franck Morschhauser, MD, Martin Gramatzki, MD, Philippe Solal-Celigny, MD, PhD, Pier L. Zinzani, MD, Andreas Engert, MD, Bertrand Coiffier, MD, Dieter Hoelzer, MD, PhD, Nick Teoh, PhD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Ivan D. Horak, MD, Thomas A. Lister, MD

Blood (2005) 106 (11): 4796.

https://doi.org/10.1182/blood.V106.11.4796.4796

Published: 2005

Journal Articles

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

Franck Morschhauser, John P. Leonard, Bertrand Coiffier, Marie-Odile Petillon, Morton Coleman, Amina Bahkti, Puja Sapra, Nick Teoh, William A. Wegener, Ivan D. Horak, David M. Goldenberg

Blood (2005) 106 (11): 2428.

https://doi.org/10.1182/blood.V106.11.2428.2428

Published: 2005

Journal Articles

Preclinical Pharmacology and Toxicology of Humanized Anti-B-Cell Antibodies (Anti-CD22 and Anti-CD20) in Cynomolgus Monkeys (CM).

Puja Sapra, PhD, Gary Kikuchi, Ph.D, Ashwini Venkatasamy, BS, Marianne K. Hayes, Ph.D, Christina M. Satterwhite, Ph.D, Darren Warren, Ph.D, Mark D. Walker, DVM, David M. Goldenberg, M.D, Ivan D. Horak, M.D

Blood (2005) 106 (11): 1471.

https://doi.org/10.1182/blood.V106.11.1471.1471

Published: 2005

Journal Articles

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

Rhona Stein, Zhengxing Qu, Thomas M. Cardillo, Susan Chen, Adriane Rosario, Ivan D. Horak, Hans J. Hansen, David M. Goldenberg

Blood (2004) 104 (12): 3705–3711.

https://doi.org/10.1182/blood-2004-03-0890

Published: 2004

Journal Articles

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Puja Sapra, PhD, Rhona Stein, PhD, Jennifer Pickett, PhD, Serengulam V. Govindan, PhD, Thomas M. Cardillo, PhD, Christopher Damoci, BS, Agatha Sheerin, BS, Hans J. Hansen, PhD, Ivan D. Horak, MD, Gary L. Griffiths, PhD, David M. Goldenberg, ScD, MD

Blood (2004) 104 (11): 3287.

https://doi.org/10.1182/blood.V104.11.3287.3287

Published: 2004

Journal Articles

Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody.

Sailaja S. Vanama, PhD, Puja Sapra, PhD, Hans J. Hansen, PhD, Ivan D. Horak, MD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD

Blood (2004) 104 (11): 3289.

https://doi.org/10.1182/blood.V104.11.3289.3289

Published: 2004

Journal Articles

ICSBP Gene Deficient Mice Are Highly Susceptible to the Development of Graft-versus-Host Disease (GVHD) Following Administration of Delayed Donor Lymphocyte Infusions (DLI).

Corinna Leng, MD, Simone Lusatis, Ivan D. Horak, PhD, Antonio Pezzutto, MD, Markus Y. Mapara, MD

Blood (2004) 104 (11): 4988.

https://doi.org/10.1182/blood.V104.11.4988.4988

Published: 2004

NARROW

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Marked Therapeutic Efficacy of a Novel Polyethyleneglycol-SN38 Conjugate, EZN-2208, in Xenograft Models of Non-Hodgkin’s Lymphoma.

Recombinant Human Mannose-Binding Lectin (rhMBL) Binds to Human and Mouse Cancer Cells and Elicits Antitumor Activity in a MBL Knockout Mouse Model of Murine Cancer.

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG 4 antibody immunotoxin

Preclinical Safety and Efficacy of Two Novel Immunotoxins Consisting of Ranpirnase (Rap) Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody in Human Non-Hodgkin’s Lymphoma Xenografts.

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

Preclinical Pharmacology and Toxicology of Humanized Anti-B-Cell Antibodies (Anti-CD22 and Anti-CD20) in Cynomolgus Monkeys (CM).

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody.

ICSBP Gene Deficient Mice Are Highly Susceptible to the Development of Graft-versus-Host Disease (GVHD) Following Administration of Delayed Donor Lymphocyte Infusions (DLI).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only